Dismod 500
- Pharmacodynamic properties:
Etamsylate is a synthetic antihaemorrhagic and angioprotective
drug acting on the first step of haemostasis (endothelium-platelet
interaction). By improving platelet adhesiveness and restoring
capillary resistance, it is able to reduce bleeding time and blood
losses.
Etamsylate has no vasoconstrictor action, it does not influence
fibrinolysis nor modify the plasma coagulation factors.
- Pharmacokinetic properties:
- Etamsylate is slowly absorbed from the gastrointestinal tract. After
oral administration of 500mg of etamsylate, its maximum plasma
level,i.e. 15 μg/ml, is reached at 4 h, but bioavailability is not
known. The binding rate to plasma proteins is about 95%. Plasma
half-life is about 3.7 h. About 72% of the administered dose are
excreted in the first 24 h-in urine; the molecule is excreted
unchanged.